卵巢子宫内膜异位囊肿「一步法」二氧化碳光纤激光汽化术与囊肿剥除术后的复发率:一项3年随访研究
回顾性研究纳入125例子宫内膜异位囊肿患者,比较腹腔镜下囊肿剥除术(组1)与二氧化碳光纤激光汽化术(组2)的术后复发率。平均随访29±13个月,囊肿复发率组1为6.3%(n=4)vs 组2为4.9%(n=3)(p=.74),疼痛复发率组1为7.8%(5例)vs 组2为9.8%(6例)(p=.67)。结论提示一步法二氧化碳光纤激光汽化术的复发率与囊肿剥除术相当,且为保留卵巢组织的技术。
要点
- 囊肿剥除术组囊肿复发率6.3%(n=4),激光汽化术组4.9%(n=3),两组无显著差异(p=.74)。
- 疼痛复发率囊肿剥除术组7.8%(5例)vs 激光汽化术组9.8%(6例),无显著差异(p=.67)。
- 手术时囊肿平均直径>5 cm是囊肿复发的独立不良预后因素(p=.008;OR 2.21;95%CI 1.19-3.32)。
核心结论
- 本研究提示一步法二氧化碳光纤激光汽化术可能有效用于子宫内膜异位囊肿治疗,其复发率与囊肿剥除术后相当,且具有保留卵巢组织的优势。
研究设计与样本
- 回顾性研究,前瞻性记录数据;设置:大学医院;纳入125例子宫内膜异位囊肿患者。
- 患者接受标准化腹腔镜囊肿剥除术(组1)或二氧化碳光纤激光囊肿汽化术(组2)。
- 术后纳入长期监测计划,定期临床随访检查囊肿和/或症状复发;子宫内膜异位囊肿复发定义为经阴道超声发现手术卵巢上出现的典型囊性结构(>10 mm)。
- 主要终点为两组复发率的比较;次要终点为两组子宫内膜异位症相关疼痛复发的评估;其他分析终点包括子宫内膜异位囊肿复发和症状复发的危险因素识别。
- 平均随访29±13个月(范围13-49个月)。
主要发现
- 卵巢子宫内膜异位症复发:囊肿剥除术组6.3%(n=4)vs 二氧化碳光纤激光汽化术组4.9%(n=3)(p=.74)。
- 子宫内膜异位症相关疼痛复发:组1为5例(7.8%)vs 组2为6例(9.8%)(p=.67)。
- 手术时囊肿平均直径>5 cm是囊肿复发的唯一独立不良预后指标(p=.008;OR 2.21;95%CI 1.19-3.32)。
- 手术时存在深部子宫内膜异位症(p=.032;OR 4.60;95%CI 1.14-18.57)和停用激素治疗(p=.015;OR 3.18;95%CI 1.25-8.06)是疼痛复发的独立不良预后指标。
临床怎么用
- 原文未据此给出推荐;研究结论提示一步法二氧化碳光纤激光汽化术可能与囊肿剥除术复发率相当,且为保留卵巢组织的技术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: To assess postoperative recurrence rates in patients with endometriomas managed by either "one-step" CO2 fiber laser vaporization or cystectomy. DESIGN: Retrospective study with prospective recording of data. SETTING: University hospital. PATIENTS: One hundred twenty-five patients with symptomatic endometriomas. INTERVENTIONS: Patients underwent a standardized laparoscopic stripping technique (group 1) or cyst vaporization with CO2 fiber laser (group 2). After surgery, patients were incorporated in a prolonged surveillance program with periodic clinical follow-up to check for recurrence of the cyst and/or recurrence of symptoms. Endometrioma recurrence was defined as an ovarian cyst (>10 mm) with a typical aspect arising on the operated ovary identified by transvaginal ultrasound. MEASUREMENTS AND MAIN RESULTS: The primary endpoint was the comparison of recurrence rates between the 2 groups. The secondary endpoint was the evaluation of endometriosis-related pain recurrence in the 2 groups. Other endpoints selected for analysis included the identification of risk factors for the recurrence of endometrioma and of endometriosis-related symptoms. The mean follow-up was 29 ± 13 months (range, 13-49). Recurrence of ovarian endometriosis was recorded in 6.3% of patients (n = 4) treated with cystectomy and in 4.9% of patients (n = 3) managed with CO2 fiber laser (p = .74). Recurrence of endometriosis-related pain was observed in 5 patients (7.8%) in group 1 and in 6 patients (9.8%) in group 2 (p = .67). Mean endometrioma diameter > 5 cm at the time of surgery was identified as the only independent poor prognostic indicator for cyst recurrence (p = .008; odds ratio [OR], 2.21; 95% confidence interval [CI], 1.19-3.32). Moreover, the presence of deep endometriosis at surgery (p = .032; OR, 4.60; 95% CI, 1.14-18.57) and discontinuation of hormonal treatment (p = .015; OR, 3.18; 95% CI, 1.25-8.06) were independent poor prognostic indicators for pain recurrence. CONCLUSION: This study suggests that one-step CO2 fiber laser vaporization may be effective for endometrioma treatment because it is associated with recurrence rates comparable with those occurring after cystectomy, with the advantage of being an ovarian tissue-sparing technique.
引用
- Candiani M, Ottolina J, Schimberni M, et al. Recurrence Rate after "One-Step" CO2 Fiber Laser Vaporization versus Cystectomy for Ovarian Endometrioma: A 3-Year Follow-up Study. J Minim Invasive Gynecol. 2019. PMID: 31377455. doi:10.1016/j.jmig.2019.07.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。